Quéro L, Labidi M, Bollet M, Bommier C, Guillerm S, Hennequin C, Thieblemont C. Radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma. World J Gastrointest Oncol 2021; 13(10): 1453-1465 [PMID: 34721777 DOI: 10.4251/wjgo.v13.i10.1453]
Corresponding Author of This Article
Laurent Quéro, MD, MSc, PhD, Professor, Department of Radiation Oncology, AP-HP, Saint Louis Hospital, 1 Avenue Claude Vellefaux, Paris 75010, France. laurent.quero@aphp.fr
Research Domain of This Article
Oncology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Oct 15, 2021; 13(10): 1453-1465 Published online Oct 15, 2021. doi: 10.4251/wjgo.v13.i10.1453
Radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma
Laurent Quéro, Mouna Labidi, Marc Bollet, Côme Bommier, Sophie Guillerm, Christophe Hennequin, Catherine Thieblemont
Laurent Quéro, Mouna Labidi, Sophie Guillerm, Christophe Hennequin, Department of Radiation Oncology, AP-HP, Saint Louis Hospital, Paris 75010, France
Laurent Quéro, Côme Bommier, Christophe Hennequin, Catherine Thieblemont, Faculty of Medicine, Université de Paris, Paris 75005, France
Marc Bollet, Department of Radiation Oncology, Hartmann Oncology Radiotherapy Group, Levallois-Perret 92044, France
Catherine Thieblemont, Hemato-Oncology, DMU DHI, AP-HP, Saint Louis Hospital, Paris 75010, France
Author contributions: Quéro L designed, researched and analyzed the literature, and helped write the paper; Labidi M, Bollet M, Guillerm S, Hennequin C and Thieblemont C analyzed the literature, and helped write the paper.
Conflict-of-interest statement: The authors have no conflict of interest related to the manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Laurent Quéro, MD, MSc, PhD, Professor, Department of Radiation Oncology, AP-HP, Saint Louis Hospital, 1 Avenue Claude Vellefaux, Paris 75010, France. laurent.quero@aphp.fr
Received: March 6, 2021 Peer-review started: March 6, 2021 First decision: June 4, 2021 Revised: July 9, 2021 Accepted: August 30, 2021 Article in press: August 30, 2021 Published online: October 15, 2021 Processing time: 221 Days and 2.1 Hours
Abstract
Gastric mucosa-associated lymphoid tissue (MALT) lymphoma is a rare disease which is often associated with Helicobacter pylori (H. pylori) infection. First-line treatment of stage IE and IIE localized gastric MALT lymphoma is based on the eradication of H. pylori. The presence of H. pylori resistance factors such as translocation t (11;18), peri-gastric lymph node involvement and the degree of tumor infiltration of the gastric wall; or lack of response to antibiotic therapy are two main indications to treat with definitive radiotherapy (RT). RT is an effective treatment in localized gastric MALT lymphoma. A moderate dose of 30 Gy allows a high cure rate while being well tolerated. After treatment, regular gastric endoscopic follow-up is necessary to detect a potential occurrence of gastric adenocarcinoma.
Core Tip: In this review, after Helicobacter pylori eradication failure, radiotherapy is an effective and well tolerated treatment in localized gastric mucosa-associated lymphoid tissue lymphoma. A moderate dose of 30 Gy allows a high cure rate while being well tolerated. Long-term gastric endoscopy follow-up is necessary to detect a possible occurrence of a stomach carcinoma.
